Tacrolimus dose adjustments after the conversion
Eight patients from the expressor group (28.6%) and seven patients from
the non-expressor group (21.9%) required an increase in the dose of
extended-release tacrolimus during the stud period. The dose of
tacrolimus was decreased in two patients from the expressor group
(7.1%) and in three patients from the non-expressor group (9.4%). The
frequency of tacrolimus dose adjustment did not differ significantly
between the study groups (P = 0.787).